Binding mode analysis of topoisomerase inhibitors, 6-arylamino-7-chloro- quinazoline-5,8-diones, within the cleavable complex of human topoisomerase I and DNA

Archives of Pharmacal Research

Volumn 30, Issue 12, 2007, Pages 1526-1535

  Choi, Inhee ^a   Kim, Choonmi ^a   Choi, Sun ^a  

^a Ewha Womans University   (South Korea)

Author keywords

6 Arylamino 7 chloro quinazoline 5,8 dione; Binding modes; Flexible docking; Inhibitory activity; QXP; Topoisomerase I DNA complex

Indexed keywords

EID: 38049144298     PISSN: 02536269     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02977321     Document Type: Article

References (26)

1. Bailly, C., Topoisomerase I poisons and suppressors as anticancer drugs. Curr. Med. Chem., 7, 39-58 (2000).
2. Capranico, G. and Binaschi, M., DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim. Biophys. Acta., 1400, 185-194 (1998).
3. Cho, W. -J., Min, S. Y., Le, T. N., and Kim, T. S., Synthesis of new 3-arylisoquinolinamines: effect on topoisomerase I inhibition and cytotoxicity. Bioorg. Med. Chem. Lett., 13, 4451-4454 (2003).
4. Chrencik, J. E., Staker, B. L., Burgin, A. B., Pourquier, P., Pommier, Y., Stewart, L., and Redinbo, M. R., Mechanisms of camptothecin resistance by human topoisomerase I mutations. J. Mol. Biol., 339, 773-784 (2004).
5. Cotesta, S., Giordanetto, F., Trosset, J. -Y., Crivori, P., Kroemer, R. T., Stouten, P. F. W., and Vulpetti, A., Virtual screening to enrich a compound collection with CDK2 inhibitors using docking, scoring, and composite scoring models. Proteins, 60, 629-643 (2005).
6. Dallavalle, S., Merlini, L., Morini, G., Musso, L., Penco, S., Beretta, G. L., Tinelli, S., and Zunino, F., Synthesis and cytotoxic activity of substituted 7-aryliminomethyl derivatives of camptothecin. Eur. J. Med. Chem., 39, 507-513 (2004).
7. Del Poeta, M., Chen, S. F., Von Hoff, D., Dykstra, C. C., Wani, M. C., Manikumar, G., Heitman, J., Wall, M. E., and Perfect, J. R., Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrob. Agents Chemother., 43, 2862-2868 (1999).
8. Fan, Y., Weinstein, J. N., Kohn, K. W., Shi, L. M., and Pommier, Y., Molecular modeling studies of the DNA-topoisomerase I ternary cleavable complex with camptothecin. J. Med. Chem., 41, 2216-2226 (1998).
9. Interthal, H., Quigley, P. M., Hol, W. G., and Champoux, J. J., The role of lysine 532 in the catalytic mechanism of human topoisomerase I. J. Biol. Chem., 279, 2984-2992 (2004).
10. Kellenberger, E., Rodrigo, J., Muller, P., and Rognan, D., Comparative Evaluation of Eight Docking Tools for Docking and Virtual Screening Accuracy. Proteins, 57, 225-242 (2004).
11. Kerrigan, J. E. and Pilch, D. S., A structural model for the ternary cleavable complex formed between human topoisomerase I, DNA, and camptothecin, Biochemistry, 40, 9792-9798 (2001).
12. Kerrigan, J. E., Pilch, D. S., Ruchelman, A. L., Zhou, N., Liu, A., Liu, L., and LaVoie, E. J., 5H-8,9-Dimethoxy-5-(2-N,N-dimethylaminoethyl) dibenzo[c,h][1 and 6]naphthyridin-6-ones and related compounds as TOP1-targeting agents: influence of structure on the ternary cleavable complex formation. Bioorg. Med. Chem. Lett., 13, 3395-3399 (2003).
13. Kettmann, V., Kost'alova, D., and Holtje, H. D., Human topoisomerase I poisoning: docking protoberberines into a structure-based binding site model. J. Comput. Aided. Mol. Des., 18, 785-796 (2004).
14. Kjeldsen, E., Svejstrup, J. Q., Gromova, II., Alsner, J., and Westergaard, O., Camptothecin inhibits both the cleavage and religation reactions of eukaryotic DNA topoisomerase I. J. Mol. Biol., 228,1025-1030 (1992).
15. Laco, G. S., Collins, J. R., Luke, B. T., Kroth, H., Sayer, J. M., Jerina, D. M., and Pommier, Y., Human topoisomerase I inhibition: docking camptothecin and derivatives into a structurebased active site model. Biochemistry, 41, 1428-1435 (2002).
16. Lauria, A., Ippolito, M., and Almerico, A. M., Molecular docking approach on the Topoisomerase I inhibitors series included in the NCI anti-cancer agents mechanism database. J. Mol. Model, 13, 393-400 (2007).
17. Marco, E., Laine, W., Tardy, C., Lansiaux, A., Iwao, M., Ishibashi, F., Bailly, C., and Gago, F., Molecular determinants of topoisomerase I poisoning by lamellarins: Comparison with camptothecin and structure-activity relationships. J. Med. Chem., 48, 3796-3807 (2005).
18. McMartin, C. and Bohacek, R. S., QXP: Powerful, rapid computer algorithms for structure-based drug design. J. Comput. Aided Mol. Des., 11, 333-344 (1997).
19. Park, H. J., Kim, Y. S., Kim, J. S., Lee, E. J., Yi, Y. J., Hwang, H. J., Suh, M. E., Ryu, C. K., and Lee, S. K., 6-Arylamino-7-chloroquinazoline-5,8- diones as novel cytotoxic and DNA topoisomerase inhibitory agents. Bioorg. Med. Chem. Lett., 14, 3385-3388 (2004).
20. Pommier, Y., Pourquier, P., Fan, Y., and Strumberg, D., Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta., 1400, 83-106 (1998).
21. Pommier, Y., Kohlhagen, G., Laco, G. S., Kroth, H., Sayer, J. M., and Jerina, D. M., Different effects on human toposiomerase I by minor groove and intercalated deoxyguanosine adducts derived from two polycyclic aromatic hydrocarbon diol epoxides at or near a normal cleavage site. J. Biol. Chem., 277, 13666-13672 (2002).
22. Redinbo, M. R., Champoux, J. J., and Hol, W. G., Novel insights into catalytic mechanism from a crystal structure of human topoisomerase I in complex with DNA. Biochemistry, 39, 6832-6840 (2000).
23. Staker, B. L., Hjerrild, K., Feese, M. D., Behnke, C. A., Burgin, A. B., and Stewart, L., The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl. Acad. Sci., 99,15387-15392 (2002).
24. Staker, B. L., Feese, M. D., Cushman, M., Pommier, Y., Zembower, D., Stewart, L., and Burgin, A. B., Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex. J. Med. Chem., 48, 2336-2345 (2005).
25. Silverman, R. B., The organic chemistry of drug design and drug action. Academic Press, San Diego, CA, USA (2004).
26. Urasaki, Y., Laco, G. S., Pourquier, P., Takebayshi, Y., Kohlhage, G., Gioffre, C., Zhang, H., Chatterjee, D., Pantazis, P., and Pommier, Y., Characterization of a novel topoisomerase I mutation from a camptothecin- resistant human prostate cancer cell line. Cancer Res., 61, 1964-1969 (2001).